Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: Relationship to outcome in schizophrenia

Journal of Clinical Psychiatry

Volumn 65, Issue 7, 2004, Pages 940-947

  Zhang, Xiang Yang ^a,b,c   Zhou, Dong Feng ^a   Cao, Lian Yuan ^b   Zhang, Pei Yan ^b   Wu, Gui Ying ^b   Shen, Yu Cun ^a  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^b BEIJING HUILONGGUAN HOSPITAL   (China)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; BLOOD; CELLULAR IMMUNITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOLOGY; MALE; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HALOPERIDOL; HOSPITALIZATION; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; INTERLEUKIN-6; INTERLEUKIN-8; MALE; RADIOIMMUNOASSAY; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 4444240323     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0710     Document Type: Article

References (54)

1. Muller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:1-33 (Pubitemid 28096427)
2. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000;157:683-694 (Pubitemid 30249643)
3. Rothermundt M, Arolt V, Bayer TA. Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun 2001;15:319-339 (Pubitemid 34044519)
4. Zalcman S, Green-Johnson JM, Murray L, et al. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 1994;643:40-49 (Pubitemid 24115074)
5. Maes M, Bocchio Chiavetto L, Bignotti S, et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 2000;10:119-124 (Pubitemid 30120041)
6. Maes M, Chiavetto LB, Bignotti S, et al. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 2002;54:281-291 (Pubitemid 34304221)
7. Rapaport MH, McAllister CG, Kim YS, et al. Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients. Biol Psychiatry 1994;35:767-771 (Pubitemid 24164997)
8. Ganguli R, Yang Z, Shurin G, et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 1994;51:1-10 (Pubitemid 24056866)
9. Xu HM, Wei J, Hemmings GP. Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia. Br J Psychiatry 1994;164:251-253 (Pubitemid 24077363)
10. Maes M, Bosmans E, Calabrese J, et al. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995;29:141-152
11. Naudin J, Mege JL, Azorin JM, et al. Elevated circulating levels of IL-6 in schizophrenia. Schizophr Res 1996;20:269-273 (Pubitemid 26232971)
12. Rapaport MH, McAllister CG, Pickar D, et al. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res 1997;25:123-129 (Pubitemid 27245134)
13. Maes M, Bosmans E, Kenis G, et al. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 1997;26:221-225
14. Lin A, Kenis G, Bignotti S, et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 1998;32:9-15 (Pubitemid 28338119)
15. Van Kammen DP, McAllister-Sistilli CG, Kelley ME, et al. Elevated interleukin-6 in schizophrenia. Psychiatry Res 1999;87:129-136 (Pubitemid 29494972)
16. Licinio J, Seibyl JP, Altemus M, et al. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 1993;150:1408-1410 (Pubitemid 23259579)
17. McAllister CG, van Kammen DP, Rehn TJ, et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 1995;159:1291-1297
18. Kim YK, Kim L, Lee MS. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 2000;44:165-175 (Pubitemid 30657953)
19. Zhang XY, Zhou DF, Zhang PY, et al. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 2002;57:247-258 (Pubitemid 35240027)
20. Rapaport MH, McAllister CG, Pickar D, et al. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res 1997;25:123-129 (Pubitemid 27245134)
21. Gattaz WF, Dalgalarrondo P, Schroder HC. Abnormalities in serum concentrations of interleukin-2, interferon-r in schizophrenia not detected. Schizophr Res 1992;6:237-241
22. Baker I, Masserano J, Wyatt RJ. Serum cytokine concentrations in patients with schizophrenia. Schizophr Res 1996;20:199-203 (Pubitemid 26387520)
23. Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994;89:346-351 (Pubitemid 24157957)
24. Ganguli R, Brar JS, Solomon W, et al. Altered IL-2 production in schizophrenia: association between clinical state and autoantibody production. Psychiatry Res 1992;44:113-123 (Pubitemid 23016248)
25. Ganguli R, Brar JS, Chengappa KNR, et al. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. Arch Gen Psychiatry 1995;52:668-672
26. Kim YK, Lee MS, Suh KY. Decreased interleukin-2 production in Korean schizophrenic patients. Biol Psychiatry 1998;43:701-704 (Pubitemid 28222392)
27. Arolt V, Rothermundt M, Wandinger KP, et al. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 2000;5:150-158 (Pubitemid 30229429)
28. Zhang XY, Zhou DF, Cao LY, et al. Decreased production of interleukin-2 (IL-2), IL-2 secreting cells and CD4+ cells in medication-free patients with schizophrenia. J Psychiatr Res 2002;36:331-336 (Pubitemid 34764058)
29. Rothermundt M, Arolt V, Weitzsch C, et al. Production of cytokines in acute schizophrenic patients. Biol Psychiatry 1996;40:1294-1297 (Pubitemid 27006414)
30. O'Donnell MC, Catts SV, Ward PB, et al. Increased production of interleukin-2 but not soluble interleukin-2 receptors in unmedicated patients with schizophrenia and schizophreniform disorder. Psychiatry Res 1996;65:171-178 (Pubitemid 27072582)
31. Cazzullo CL, Sacchetti E, Galluzzo A, et al. Cytokine profiles in drug-naive schizophrenic patients. Schizophr Res 2001;47:293-298 (Pubitemid 32244114)
32. Pollmacher T, Haack M, Schuld A, et al. Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res 2000;34:369-382 (Pubitemid 32101554)
33. Pollmacher T, Hinze-Selch D, Mullingto J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996;16:403-409 (Pubitemid 26352672)
34. Akiyama K. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr Res 1999;37:97-106
35. Pollmacher T, Hinze-Selch D, Fenzel T, et al. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am J Psychiatry 1997;154:1763-1765 (Pubitemid 27516599)
36. Bessler H, Levental Z, Karp L, et al. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 1995;38:297-302
37. Rothermundt M, Arolt V, Leadbeater J, et al. Cytokine production in unmedicated and treated schizophrenic patients. Neuroreport 2000;11:3385-3388 (Pubitemid 30797822)
38. Zhang XY, Zhou DF, Cao LY, et al. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. Int Clin Psychopharmacol 2001;16:325-330
39. Lohr JB, Flynn K. Smoking and schizophrenia. Schizophr Res 1992;8:93-102
40. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
41. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796 (Pubitemid 18222922)
42. Kim DJ, Kim W, Yoon SJ, et al. Effect of risperidone on serum cytokines. Int J Neurosci 2001;111:11-19 (Pubitemid 34000212)
43. Leykin I, Mayer R, Shinitzky M. Short and long term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 1997;37:75-86 (Pubitemid 27339022)
44. Song C, Lin A, Kenis G, et al. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr Res 2000;42:157-164 (Pubitemid 30163081)
45. Lapchak PA. A role of interleukin-2 in the regulation of striatal dopaminergic function. Neuroreport 1992;3:165-168
46. Denicoff KD, Rubinoff DR, Papa MZ, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987;107:293-300 (Pubitemid 17136929)
47. Andreasen NC. The Scale for the Assessment of Positive Symptoms in Schizophrenia (SAPS). Iowa City, Ia: University of Iowa; 1984
48. Petitto JM, McCarthy DB, Rinker CM, et al. Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2. J Neuroimmunol 1997;73:183-190 (Pubitemid 27105285)
49. Muller N, Hofschuster E, Ackenheil M, et al. T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy. Acta Psychiatr Scand 1993;87:66-71 (Pubitemid 23024868)
50. Westermann J, Pabst R. Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system? Immunol Today 1990;11:406-410
51. LeMay LG, Vander AJ, Kluger MJ. The effects of psychological stress on plasma interleukin-6 activity in rats. Physiol Behav 1990;47:957-961 (Pubitemid 20171700)
52. Zhou D, Kusnecov AW, Shurin MR, et al. Exposure to physical and psychological stressors elevates plasma interleukin-6: relationships to the activation of hypothalamic-pituitary-adrenal axis. Endocrinology 1993;133:2523-2530 (Pubitemid 24000698)
53. Altamura AC, Boin F, Maes M. HPA axis and cytokines dysregulation in schizophrenia: potential implication for the antipsychotic treatment. Eur Neuropsychopharmacol 1999;10:1-4
54. Haddad JJ, Saade NE, Safieh-Garabedian B. Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary- adrenal revolving axis. J Neuroimmunol 2002;133:1-19 (Pubitemid 35346723)